| Log in

CCI clears Sun-Ranbaxy merger deal with riders, asks two companies to divest some products

By PTI
08 December, 2014

The long-pending $4-billion merger between Sun Pharma and Ranbaxy today got a conditional approval from fair trade watchdog CCI, which asked the two companies to divest some key products along with other changes to the deal to address the anti-competitive issues.

The fair trade regulator’s approval comes after the first ever public scrutiny carried out by it for a merger, which was announced in April and would create India’s largest and world’s fifth biggest drug-maker.

In an order released today, the Competition Commission of India (CCI) said that it “approves the proposed combination … subject to the parties carrying out the modification to the proposed combination”.

CCI has directed Sun Pharma to divest all products containing ‘Tamsulosin + Tolterodine’ which are at present marketed and supplied under the Tamlet brand name.

Similarly, Ranbaxy would be required to divest all products containing Leuprorelin which are marketed and supplied under the Eligard brand name, among others. In all, six products will have to be divested by Ranbaxy and one by Sun.

According to the fair trade watchdog, the modification to the proposed deal aims “to maintain the existing level of competition in the relevant markets in India”.

This would need to be done through creation of a viable, effective, independent and long term competitor in the relevant markets pertaining to the divestment products, CCI said in the order.

“Ensuring that the approved purchaser of divestment product(s) has the necessary components, including transitional support arrangements to compete effectively with the merged entity in the relevant markets in India.

The combined entity would have operations in 65 countries, 47 manufacturing facilities across 5 continents, and a significant platform of speciality and generic products marketed globally.


Leave Your Comment
CCI expands probe into Sun-Ranbaxy deal

CCI expands probe into Sun-Ranbaxy deal

PTI 3 years ago
Widening its scrutiny of the multi-billion dollar Sun Pharma-Ranbaxy deal, fair...
Bain Capital-backed Emcure to buy half a dozen products from Sun Pharma-Ranbaxy

Bain Capital-backed Emcure to buy half a dozen products from Sun Pharma-Ranbaxy

Anuradha Verma 3 years ago
The Competition Commission of India (CCI) has approved the acquisition of around...
Sun Pharma gets US FTC nod to buy Ranbaxy

Sun Pharma gets US FTC nod to buy Ranbaxy

Anuradha Verma 3 years ago
The US Federal Trade Commission (FTC) has approved the proposed $4-billion...
No Comments

CCI clears Sun-Ranbaxy merger deal with riders, asks two companies to divest some products

Powered by WordPress.com VIP